Arrowstreet Capital, Limited Partnership Supernus Pharmaceuticals, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $121 Billion
- Q3 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 97,523 shares of SUPN stock, worth $3.49 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97,523Holding current value
$3.49 Million% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
60.9MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$372 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$220 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$183 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$103 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$94.3 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.92B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...